Impact Factor
3.82
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.96
986 total citations
h5-index
37
h5 depth signal
Cited share
89.5%
229 of 256
Total citations
986
Citation footprint
Metric signal
3.75
External metric anchor
Self-citation
2.2%
22 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
423
Italy
344
United Kingdom
120
Germany
91
Spain
81
Citing Fields of Research
Immunology
411
Musculoskeletal Disorders
245
Oncology
204
Immunotherapy
194
Inflammatory Bowel Diseases & Infections
123
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,779
Articles tracked across the journal lifetime
Indexed publication set
256
229 cited publications
Last 12 months
137
11.4 publications/month
Open access share
23.4%
32 OA publications in the last year
Leading citing country
United States
423 citing publications
Leading citing field
Immunology
411 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v1n1, Jan. 2001-
v1n1, Jan. 2001-
Active Coverage
Research Focus & Classification
Indexed Subjects
Musculoskeletal Disorders
Immunology
Lymphomas
Inflammatory Bowel Diseases & Infections
Hematology
Allergies
Broad Categories
Biology
Therapeutics
Separation Techniques
Musculoskeletal Disorders
Lymphomas
Immunology
Inflammatory Bowel Diseases & Infections
Hematology
MeSH Descriptors
Biological Therapy
Drug Delivery Systems
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1080/14712598.2026.2742404
Open DOI
An evaluation of sacituzumab tirumotecan for the treatment of NSCLC
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, and resistance to targeted therapy and immunotherapy represents a substantial unmet clinical need. Trophoblast cell-surface antigen 2 (TROP2)-directe...
02
DOI 10.1080/14712598.2026.2748260
Open DOI
Emerging therapeutic strategies and clinical trials in severe asthma management: current evidence and future directions
03
DOI 10.1080/14712598.2026.2746447
Open DOI
The cost of delay: foregone public expenditure savings from delayed adalimumab biosimilar listing in Australia’s Pharmaceutical Benefits Scheme
Adalimumab is among the highest-expenditure biologics under Australia's Pharmaceutical Benefits Scheme (PBS). Although the Pharmaceutical Benefits Advisory Committee recommended listing adalimumab biosimilars in 2018, reimbursement did n...
04
DOI 10.1080/14712598.2026.2746892
Open DOI
Changes in the FIB-4 index with IL-23 vs IL-17 inhibitors in psoriasis: a retrospective cohort study
05
DOI 10.1080/14712598.2026.2745576
Open DOI
Subcutaneous infliximab in inflammatory bowel disease: from pharmacokinetic principles to clinical practice
Subcutaneous infliximab (CT-P13 SC) was developed to address the pronounced peak-to-trough fluctuations of intravenous dosing and the immunogenicity driven by sub-therapeutic troughs. Through a stable steady-state pharmacokinetic profile...
06
DOI 10.1080/14712598.2026.2746176
Open DOI
Navigating TNF and il‑17 pathways in hidradenitis suppurativa: real‑world lessons and future biologic combinations
07
08
DOI 10.1080/14712598.2026.2743869
Open DOI
Redefining breast cancer treatment by precision oncology: the clinical impact of sacituzumab govitecan
09
DOI 10.1080/14712598.2026.2738707
Open DOI
Biologic therapies for adult chronic urticaria: what works, what doesn’t, and why
Chronic spontaneous urticaria (CSU) remains uncontrolled in many adults despite antihistamines and anti-immunoglobulin E (IgE) therapy. The expanding therapeutic landscape includes validated biologic options, promising investigational me...
10
DOI 10.1080/14712598.2026.2743265
Open DOI
RNA-targeting therapeutics for rare neuromuscular diseases: progress, challenges, and the path toward personalized treatment
1. Neuromuscular diseases are a heterogenous classification of disorders broadly defined as conditions causing dysfunction in muscles, motor neurons, peripheral nerves, and/or the neuromuscular jun...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.